Kissei Pharmaceutical (4547.T)

Executive Summary

Kissei Pharmaceutical is a Japanese specialty pharmaceutical company with established expertise in urology, nephrology, and rare disease therapeutics. The company operates an integrated business model combining internal R&D with strategic in-licensing and global collaborations. With 14 marketed products and a diversified pipeline, Kissei is positioned to deliver near-term value inflection. Key late-stage assets include KDT-3594, a Phase 2 candidate for Parkinson's disease that completed enrollment in April 2026, and KLH-2109, a GnRH antagonist in Phase 3 trials for endometriosis and uterine fibroids. The company's stable revenue base from commercial products provides a foundation for funding pipeline development. Recent trial completions and ongoing studies position Kissei for potential regulatory submissions and data readouts in the coming quarters, offering catalysts for share price appreciation.

Upcoming Catalysts (preview)

• Q3 2026KDT-3594 Phase 2 data readout in Parkinson's disease65% success
• H2 2026KLH-2109 Phase 3 interim analysis or enrollment completion in endometriosis60% success